12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CNV1014802: Phase II started

Convergence began a double-blind, placebo-controlled, international Phase II trial to evaluate 150 mg oral CNV1014802 thrice daily for 28 days in about 30 patients who responded...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >